Aurinia Pharmaceuticals Inc. (AUPH) shows weekly volitility of 11.62%


Aurinia Pharmaceuticals Inc. (AUPH) reported its last quarter results on 11/04/2016. This Company belongs to Medical sector.

In the last trading session, The Company traded 6.64 Million shares. The Stock Market opened sessions at 7.92 and closed at 7.7. There was a stock decrease by -0.26 percent.

According to Yahoo Finance, the price target for the company which analysts are aiming is 12. The 1-year price target of the company is 10.3.

Investors expected a price target of -0.08 for this quarter.  Zacks Investment Research gave Aurinia Pharmaceuticals Inc. (AUPH) a rating of 1.26 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.

Considering the performance, Aurinia Pharmaceuticals Inc. (AUPH)’s shares have the potential to reach a high EPS of -0.11 per share, and a low EPS of -0.16 per share in the current quarter. All of these Earnings estimates are a consensus recommendation of 3 Analysts. According to them, the median (average) EPS the company could deliver is -0.14/share. While the actual EPS the company reported in the same quarter previous year was -0.13/share.

For the quarter ending 08/05/2016, The Analyst projected that the company could deliver EPS of -0.14 while the company provided its Actual EPS of -0.21 showing a difference of -0.07 Percent between the Estimated and Actual EPS. Hence, the surprise factor was -50 percent.

Analysts estimated $-0.12/share for the previous Quarter, where Aurinia Pharmaceuticals Inc. (AUPH) reported Actual EPS of $-0.22/share with the difference of -0.1 percent and a surprise of -83.3 percent.

The 6 analysts offering 12-month price forecasts for Aurinia Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 9.00. The median estimate represents a +42.86% increase from the last price of 7.70.

For the current quarter, the highest estimate analysts provided is 140 Million and the lowest is 30 Million. These 4 Analysts are also projecting the mean revenue estimate of 80 Million. The year ago sales the company reported in the same quarter is 57 Million.

While Looking at Sales Growth (Year/est), the company is currently showing a percentage value of 60.6 percent.

Aurinia Pharmaceuticals Inc. (AUPH) topped its 52-week high price target of 10.54 on Mar 13, 2017. The company reached a 52-week low at 1.74 on Aug 15, 2016.

The company’s stock currently has 406.62 Million in market capitalization. The volatility rate is 11.62% percent and 12.06% percent each. Price per earning (ttm) stands at 0.

Company Profile:

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.